|
Facebook
Twitter
Linkedin
|
 |
 |
 |
 |
Access to Neurostat 3D-SSP for brain PET or SPECT analysis
Wednesday, 01 April 2009 07:25 | 
| Organizations - SNM |
NEUROSTAT 3D-SSP and Its Use in FDG-PET Analysis
The role of FDG brain PET for the diagnosis of Alzheimer’s disease (AD) is becoming more widely accepted. In a recent position paper published in The Lancet Neurology, leaders in the field of AD pro-posed that the research diagnostic cri-teria—and this will influence clinical diagnostic criteria—should be modi-fied, removing the need for dementia to be present.
Instead, patients with objective memory impairment alone and typical AD type findings on magnetic reso-nance imaging (MRI), cerebrospinal fluid (CSF) analysis or positron emis-sion tomography (PET) can be diag-nosed as AD before the individual is demented. It is therefore becoming increasingly important that the inter-pretation of fluorodeoxyglucose (FDG) brain studies is reliable, consistent and objective.
In recent years, a number of pro-grams have become available that allow comparison of an individual study to an age-matched, normal database. Some of these are now commercially available or supplied by PET camera vendors. An original program devel-oped by Professor Satoshi Minoshima, a past president of the Brain Imaging Council (BIC), and published in The Journal of Nuclear Medicine (1995; 36:1238–1248) is available free-of-charge. This program is called 3D-SSP/NEUROSTAT and was used for the discovery of posterior cingulate hypometabolism in AD and occipital hypometabolism in dementia with Lewy bodies (DLB).
A graphical user interface that permits this to run on a PC and pro-duce 3-D surface-extracted images of areas of significant FDG reduction in the form of Z-score maps (the number of standard deviations from the mean of a group of normal subjects) can also be freely downloaded. In conjunction with the effort by the SNM BIC to promote accurate physician diagnosis of FDG-PET scans, my colleagues and I at the Austin Hospital in Melbourne, Australia, have produced a normal da-tabase created from 25 healthy elderly persons (mean age of 72 years) with negative PiB PET scans to exclude incipient AD, normal MRI and normal scores on extensive neuropsychology testing.
Source: SNM
The role of FDG brain PET for the diagnosis of Alzheimer’s disease (AD) is becoming more widely accepted. In a recent position paper published in The Lancet Neurology, leaders in the field of AD pro-posed that the research diagnostic cri-teria—and this will influence clinical diagnostic criteria—should be modi-fied, removing the need for dementia to be present.
Instead, patients with objective memory impairment alone and typical AD type findings on magnetic reso-nance imaging (MRI), cerebrospinal fluid (CSF) analysis or positron emis-sion tomography (PET) can be diag-nosed as AD before the individual is demented. It is therefore becoming increasingly important that the inter-pretation of fluorodeoxyglucose (FDG) brain studies is reliable, consistent and objective.
In recent years, a number of pro-grams have become available that allow comparison of an individual study to an age-matched, normal database. Some of these are now commercially available or supplied by PET camera vendors. An original program devel-oped by Professor Satoshi Minoshima, a past president of the Brain Imaging Council (BIC), and published in The Journal of Nuclear Medicine (1995; 36:1238–1248) is available free-of-charge. This program is called 3D-SSP/NEUROSTAT and was used for the discovery of posterior cingulate hypometabolism in AD and occipital hypometabolism in dementia with Lewy bodies (DLB).
A graphical user interface that permits this to run on a PC and pro-duce 3-D surface-extracted images of areas of significant FDG reduction in the form of Z-score maps (the number of standard deviations from the mean of a group of normal subjects) can also be freely downloaded. In conjunction with the effort by the SNM BIC to promote accurate physician diagnosis of FDG-PET scans, my colleagues and I at the Austin Hospital in Melbourne, Australia, have produced a normal da-tabase created from 25 healthy elderly persons (mean age of 72 years) with negative PiB PET scans to exclude incipient AD, normal MRI and normal scores on extensive neuropsychology testing.
Source: SNM
Tags: FDG - fluorodeoxyglucose - AD - Alzheimer’s disease - PET - positron emis-sion tomography - CSF - cerebrospinal fluid - MRI - magnetic reso-nance imaging - BIC - Brain Imaging Council - neuropsychology
